Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222074 | 1.00 | HDAC3 (0.32) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL2151168 | 1.00 | HDAC3 (0.32) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL12574484 | 0.84 | — | — | |
| SCHEMBL29257618 | 0.84 | ALDH1A1 (0.31) | — | |
| SCHEMBL29257617 | 0.84 | ALDH1A1 (0.31) | — | |
| SCHEMBL2152321 | 0.84 | CYP2D6 (0.33) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL2152196 | 0.84 | ALDH1A1 (0.31) | — | |
| SCHEMBL29257621 | 0.84 | ALDH1A1 (0.31) | — | |
| SCHEMBL2151802 | 0.84 | ALDH1A1 (0.31) | — | |
| SCHEMBL362705 | 0.82 | TSHR (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260014260-A1 | MDM2 DEGRADER | NEWAVE PHARMACEUTICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. | 2025-03-06 | — | — | US | disclosed |
| WO-2023230059-A1 | MDM2 DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| CN-116283701-A | Compounds having the structure 4- (substituted aminomethyl) -5-neopentyl-N-substituted pyrrolidine-2-carboxamide | 中国科学院上海药物研究所 | 2023-06-23 | — | — | CN | disclosed |
| CN-115215872-A | Small molecule compound with substituted phenyl spiro [ indoline-3, 3' -pyrrolidine ] structure | 中国科学院上海药物研究所 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022159644-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2012022707-A1 | SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | BARTKOVITZ DAVID JOSEPH (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014260-A1 | MDM2 DEGRADER | MDM2, TP53, ADRM1 | HDAC3 2337/4885HDAC1 2085/4885HDAC2 3097/4885 |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | FOXM1, MDM2, FOXO1 | HDAC3 537/4885HDAC1 163/4885HDAC2 430/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | HDAC3 1077/4885HDAC1 893/4885HDAC2 1746/4885 |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | MDM2, TP53, RB1 | HDAC3 407/4885HDAC1 167/4885HDAC2 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.